Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 5/20 | 0.62 |
| ▸ | BRD4 | O60885 | 4/20 | 0.62 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | FABP7 | O15540 | 1/20 | 0.49 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | WDR91 | A4D1P6 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7678811 | 0.75 | NPC1 (0.57) | KMT2A | |
| SCHEMBL12189468 | 0.74 | ALDH1A1 (0.71) | MGLLKMT2ASMO | |
| SCHEMBL4407214 | 0.74 | CRBN (0.50) | WDR91KMT2AALOX5 | |
| SCHEMBL13065989 | 0.73 | MGLL (0.62) | MGLLKMT2AALOX5SMO | |
| SCHEMBL9836689 | 0.72 | CRBN (0.49) | WDR91 | |
| SCHEMBL9836593 | 0.72 | CRBN (0.46) | WDR91 | |
| SCHEMBL6328529 | 0.72 | BRD4 (0.54) | CREBBPBRD4 | |
| SCHEMBL5840685 | 0.71 | WDR91 (0.51) | CREBBPWDR91 | |
| SCHEMBL9375284 | 0.70 | CRBN (0.49) | WDR91 | |
| SCHEMBL6542776 | 0.69 | SMYD3 (0.54) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | claimed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | claimed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | claimed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | claimed |
| US-7071332-B2 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6706709-B2 | TREATING, FOR EXAMPLE, PROLIFERATIVE DISORDERS INCLUDING CANCER | SUGEN, INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1294688-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | Sugen, Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | SUGEN, INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2001094312-A2 | INDOLINONE DERIVATIVES AS PROTEIN KINASE/PHOSPHATASE INHIBITORS | SUGEN, INC. (US) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147586-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | CREBBP 796/4885BRD4 1204/4885GRM5 2946/4885 |
| US-20020052369-A1 | Indolinone derivatives as protein kinase/phosphatase inhibitors | PHKA1, PHKA2, PDPK1 | CREBBP 796/4885BRD4 1204/4885GRM5 2946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.